share_log

Monte Rosa Therapeutics Announced Progress Updates For Its Two Lead Programs, MRT-2359, An MGD Being Developed For MYC-Driven Solid Tumors, And MRT-6160, A VAV1-directed MGD In Development For Systemic And Neurological Autoimmune Diseases

Benzinga ·  Jun 27 07:13
  • Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024.
  • IND submission achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; initiation of Phase 1 SAD/MAD study expected this summer with Phase 1 clinical data anticipated in Q1 2025.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment